Travere Therapeutics, Inc. (TVTX) Cash Flow Statement
Travere Therapeutics, Inc. (TVTX) generated $92.7M of operating cash flow over the twelve months to 2026-06-30, spent $0 on capital expenditure and had free cash flow of $92.7M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TVTXTravere Therapeutics, Inc.Follow TVTX — free
—
Price chart with a free account
- Market cap
- 4.7B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
| Line | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -25.0 | -58.2 | -42.7 | -14.8 | -186.3 | -280.0 | -237.5 | 37.8 | 92.7 | |
| Capital expenditure | 0.7 | 0.2 | 6.8 | 5.1 | 0.2 | 0.7 | 0.0 | 0.0 | -0.0 | |
| Free cash flow | -25.7 | -58.4 | -49.5 | -19.9 | -186.5 | -280.7 | -237.5 | 37.8 | 92.7 | |
| Stock-based compensation | 19.8 | 21.1 | 23.6 | 29.6 | 38.1 | 44.2 | 36.9 | 44.9 | — |
USD millions · SEC XBRL
Travere Therapeutics, Inc. — questions
- What is Travere Therapeutics, Inc.'s operating cash flow?
- $92.7M over the twelve months to 2026-06-30.
- How much does Travere Therapeutics, Inc. spend on capital expenditure?
- $0 over the twelve months to 2026-06-30.
- What is Travere Therapeutics, Inc.'s free cash flow?
- $92.7M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Travere Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.